|
|
Exchange: |
Over The Counter |
Security
Type: |
Common |
Shares
Out: |
570,750,000 |
Market
Cap: |
91.32(M) |
Last
Volume: |
2,344,724 |
Avg
Vol: |
3,101,442 |
52
Week Range: |
$0.1165 - $0.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CytoDyn is a clinical-stage biotechnology company focused on the clinical development of treatments for multiple therapeutic indications based on its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor. Leronlimab is being investigated as a viral entry inhibitor for Human Immunodeficiency Virus. Leronlimab is also being studied in oncology, as well as other therapeutic indications, including coronavirus disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Blok Tyler |
EVP of Legal AffairsOfficer |
|
2023-08-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
250 |
|
-1% |
|
Arman Arvin Cyrus |
President |
|
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
434,782 |
1,081,334 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
16,927 |
2,184,037 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
12,008 |
183,207 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,671 |
500,090 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,234 |
2,167,110 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,807 |
171,199 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
17,922 |
2,151,876 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
16,084 |
486,419 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,714 |
160,392 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,849 |
2,133,954 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,428 |
470,335 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,824 |
147,678 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
10,292 |
137,854 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
13,020 |
457,907 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
18,793 |
2,120,105 |
|
- |
|
Arman Arvin Cyrus |
President |
|
2022-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
646,552 |
646,552 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,965 |
444,887 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,086 |
127,562 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,457 |
2,101,312 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8,313 |
120,476 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
10,516 |
435,922 |
|
- |
|
Kelly Scott A. |
CMO |
|
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
11,094 |
2,091,855 |
|
- |
|
Ray Nitya G. |
Chief Technology Officer |
|
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,588 |
425,406 |
|
- |
|
Migliarese Antonio |
CFO |
|
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
112,163 |
|
- |
|
169 Records found
|
|
Page 1 of 7 |
|
|